Business Context and Reporting Period
This Form 8-K is filed by ReShape Lifesciences Inc. (noting a discrepancy with the metadata name "Vyome Holdings, Inc") for the reporting date of June 9, 2025. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol RSLS. The filing details capital raising activities under Item 8.01 Other Events.
Key Financial Metrics
- Public Offering Proceeds: Gross proceeds of $2,636,510 from the sale of 1,054,604 shares at $2.50 per share.
- ATM Offering Activity: $3,642,564 in shares sold under the At-The-Market (ATM) program since its commencement on May 30, 2025.
- Remaining ATM Capacity: $3,420,926 remaining available under the $9,700,000 total ATM agreement with Maxim Group LLC.
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the execution of a public offering and continued sales under an existing ATM program. The company reduced its available ATM capacity by approximately $6.28 million ($3.64 million sold previously plus $2.64 million in the new public offering) within a nine-day period.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operations, or specific risk factors beyond standard securities law disclaimers. The document explicitly states it is not an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the correct registrant name (ReShape Lifesciences Inc. vs. Vyome Holdings, Inc.) to ensure accurate data attribution.
- Confirm the net proceeds after deducting placement agent fees and offering expenses, as only gross proceeds are listed.
- Review the company's most recent 10-Q or 10-K for current cash balances and liquidity status, as this 8-K does not provide them.
- Monitor the remaining $3.42 million ATM capacity for potential future dilution.